Günümüzde hızla gelişmekte olan immünoterapi tedavilerinden biri de son yıllarda gelişimi hızlanan kimerik antijen reseptörü [chimeric antigen receptor (CAR)] T hücre tedavisidir. CAR-T hücreleri, genetik olarak tasarlanmış yapay T hücresi reseptörleri, tümör antijenlerinin tanınmasını sağlar. Teorik olarak, bu modifiye edilmiş hücreler, herhangi bir antijene karşı yönlendirilebilmekte ve hedef tümör hücrelerini öldürme yeteneğini artırabilmektedir. CAR-T hücre tedavisinin uygulanması, hücre üretimi, aferez ürünlerinin takibi, taşınması ve ciddi toksisitelerin yönetimini içeren karmaşık bir süreci içerir. CART hücre tedavisinin başarısı genel olarak, uygulamayı yapan ve bakım veren sağlık personelinin eğitimli olması ile kurumun toksisitelerinin yönetebilecek yeterli altyapıya sahip olmasına bağlıdır. Klinik hemşirelerinin toksisite semptomlarını tanıma ve tedavinin etkin olarak ilerlemesini desteklemek için yeni tedavi yöntemleri konusunda eğitilmesi ve bu konuda farkındalık oluşturulması önemlidir. Yaygın görülen toksisiteler; sitokin salınım sendromu, CAR-T hücre tedavisi ile ilişkili ensefalopati sendromu'dur. Bu çalışmada, CAR-T hücre tedavisinin başarılı bir şekilde uygulanabilmesi için tedavinin içeriği ve hemşirelik yönetimi açıklanmıştır. Hemşirelik yönetimi genel olarak; infüzyon süreci yönetimi, komplikasyonların yönetimi ve hasta eğitimi başlığı altında ele alınmıştır.
Anahtar Kelimeler: İmmünoterapi; CD19 antijen; hemşirelik bakımı
One of the rapidly developing immunotherapy therapies is chimeric antigen receptor (CAR) T cell therapy which has been accelerating in recent years. CAR-T cells, genetically engineered artificial T cell receptors, allow the recognition of tumor antigens. Theoretically, these modified cells can be directed against any antigen and increase the ability to kill target tumor cells. CAR-T cell therapy involves a complex process involving cell production, tracking, transport of apheresis products, and management of serious toxicities. The success of CAR-T cell therapy generally depends on the fact that the health personnel performing the care and the care given are trained and the institution has sufficient infrastructure to manage the toxicities. It is important that clinical nurses are trained and raised awareness of new treatment methods to recognize the symptoms of toxicity and to support the effective progress of treatment. Common toxicities are cytokine release syndrome, CAR-T cell therapy-associated encephalopathy syndrome. In this review, the content of the treatment and nursing management are explained for the successful implementation of CAR-T cell therapy. Nursing management in general; infusion process management, complications management and patient education.
Keywords: Immunotherapy; CD19 antigens; nursing care
- American Cancer Society (ACS). Monoclonal antibodies to treat cancer; 2016. Retrieved from http:// bit.ly/2lbQs57
- Halton E, Llerandi D, Diamonte C, Quintanilla H, Miale-Mayer D. Developing infrastructure: managing patients with cancer undergoing CAR T-cell therapy. Clin J Oncol Nurs. 2017;21(2 Suppl):35-40. [Crossref] [PubMed]
- Holzinger A, Barden M, Abken H. The growing world of CAR T cell trials: a systematic review. Cancer Immunol Immunother. 2016;65(12):1433-50. [Crossref] [PubMed]
- Drokow EK, Ahmed HAW, Amponsem-Boateng C, Akpabla GS, Song J, Shi M, et al. Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis. Ther Clin Risk Manag. 2019:15:637-46. [Crossref] [PubMed] [PMC]
- Şahin DG, Akay OM. [Chimeric antigen receptor-T-cell therapy]. Turkiye Klinikleri J Intern Med. 2019;4(3):139-46. [Crossref]
- Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist. 2016;21(5):608-17. [Crossref] [PubMed] [PMC]
- Morrison F. Nursing management for adult recipients of CAR T-19 therapy. Nursing 2019 Critical Care. 2019;14(2):31-6. [Crossref]
- Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433-44. [Crossref] [PubMed]
- Callahan C, Baniewicz D, Ely B. CAR T-cell therapy: pediatric patients with relapsed and refractory acute lymphoblastic leukemia. Clin J Oncol Nurs. 2017;21(2 Suppl):22-8. [Crossref] [PubMed]
- Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16(1):45-63. [Crossref] [PubMed] [PMC]
- Yá-ez L, Sánchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019;3(2):e186. [Crossref] [PubMed] [PMC]
- Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531-44.
- Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med. 2017;377(26):2545-54. [Crossref] [PubMed] [PMC]
- Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-48. [Crossref] [PubMed] [PMC]
- Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224-5.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62. [Crossref] [PubMed] [PMC]
- Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018;15(4):218. [Crossref] [PubMed]
- Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-95.
- EMA. Kymriah-epar-product-information. Available at: https://www.ema. europa.eu/documents/product-information/kymriah-epar-productinformation_en.pdf. Accessed July 14, 2019.
- EMA. Yescarta-epar-product-information. Available at: https://www.ema. europa.eu/documents/product-information/yescarta-epar-productinformation_en.pdf. Accessed: July 14, 2019.
- Smith L, Venella K. Cytokine release syndrome: inpatient care for side effects of CAR T-cell therapy. Clin J Oncol Nurs. 2017;21(2 Suppl):29-34. [Crossref] [PubMed]
- Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;20(3):16011. [Crossref] [PubMed] [PMC]
- The ELIANA Clinical Trial Fact Sheet; 2018. p.2. Available at: https://novartis.gcs-web.com/static-files/110bee95-5916-483f-a0c9-20128105005f. Accessed: May 24, 2019.
- The JULIET Clinical Trial Fact Sheet; 2017. p.2. Available at: https://novartis.gcs-web.com/static-files/6c49fca0-ee27-4f63-8d09-9a0f73760bfe. Accessed: May 24, 2019.
- Chimeric Antigen Receptor (CAR) Cell Therapy Toxicity assessment and management-adult. department of clinical effectiveness V2Approved by the Executive Committee of the Medical Staff on 10/31/2017. p.28. Available at: https://www.mdanderson.org/documents/for-physicians/algorithms/clinical-management/clin-management-cytokine-release-web-algorithm.pdf.
- Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863-71. [Crossref] [PubMed] [PMC]
- McConville H, Harvey M, Callahan C, Motley L, Difilippo H, White C. CAR T-cell therapy effects: review of procedures and patient education. Clin J Oncol Nurs. 2017;21(3):E79. [Crossref]
- Brogren J. Initiating a chemotherapy discharge teaching class on a mixed medical oncology unit. Denver, CO: Oncology Nursing Society 42nd Annual Congress; 2017.
.: Process List